Identification

Name
Moexipril
Accession Number
DB00691  (APRD01120)
Type
Small Molecule
Groups
Approved
Description

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Structure
Thumb
Synonyms
  • Moexipril
  • Moexiprilum
External IDs
RS-10085
Product Ingredients
IngredientUNIICASInChI Key
Moexipril HydrochlorideQ1UMG3UH4582586-52-5JXRAXHBVZQZSIC-JKVLGAQCSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
UnivascTablet, film coated15 mg/1OralUcb Inc1995-07-152016-02-25Us
UnivascTablet, film coated7.5 mg/1OralUcb Inc1995-07-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Moexipril HydrochlorideTablet15 mg/1OralPhysicians Total Care, Inc.2004-04-27Not applicableUs
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralTeva2003-05-08Not applicableUs
Moexipril HydrochlorideTablet7.5 mg/1OralApotex Corporation2008-06-09Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralCarilion Materials Management2003-05-08Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2010-12-31Not applicableUs68462 0208 01 nlmimage10 7a1b3d59
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralCarilion Materials Management2003-05-08Not applicableUs00093 0017 01 nlmimage10 6629b33d
Moexipril HydrochlorideTablet, film coated7.5 mg/1OralAvera Mc Kennan Hospital2015-08-10Not applicableUs
Moexipril HydrochlorideTablet7.5 mg/1OralPhysicians Total Care, Inc.2008-08-14Not applicableUs
Moexipril HydrochlorideTablet, film coated15 mg/1OralTeva2003-05-08Not applicableUs00093 5150 01 nlmimage10 2e29974c
Moexipril HydrochlorideTablet15 mg/1OralApotex Corporation2008-06-09Not applicableUs
International/Other Brands
Uniretic / Univasc
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (25 mg/1)Tablet, film coatedOralAv Kare, Inc.2017-04-03Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralTeva2007-03-07Not applicableUs00093 5214 01 nlmimage10 5a2bad7d
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs68462 0207 01 nlmimage10 37411ba8
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAv Kare, Inc.2017-04-03Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (15 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralGlenmark Pharmaceuticals Inc.,Usa2010-03-18Not applicableUs
Moexipril Hydrochloride and HydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralTeva2007-03-07Not applicableUs00093 5213 01 nlmimage10 632bb1fd
Moexipril hydrochloride and hydrochlorothiazideMoexipril Hydrochloride (7.5 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralHeritage2014-03-20Not applicableUs
Categories
UNII
WT87C52TJZ
CAS number
103775-10-6
Weight
Average: 498.5681
Monoisotopic: 498.236601452
Chemical Formula
C27H34N2O7
InChI Key
UWWDHYUMIORJTA-HSQYWUDLSA-N
InChI
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
IUPAC Name
(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]@H](C)C(=O)N1CC2=CC(OC)=C(OC)C=C2C[[email protected]]1C(O)=O

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Pharmacodynamics

Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Mechanism of action

Moexipril is a prodrug for moexiprilat, which inhibits ACE in humans and animals. The mechanism through which moexiprilat lowers blood pressure is believed to be primarily inhibition of ACE activity. ACE is a peptidyl dipeptidase that catalyzes the conversion of the inactive decapeptide angiotensin I to the vasoconstrictor substance angiotensin II. Angiotensin II is a potent peripheral vasoconstrictor that also stimulates aldosterone secretion by the adrenal cortex and provides negative feedback on renin secretion. ACE is identical to kininase II, an enzyme that degrades bradykinin, an endothelium-dependent vasodilator. Moexiprilat is about 1000 times as potent as moexipril in inhibiting ACE and kininase II. Inhibition of ACE results in decreased angiotensin II formation, leading to decreased vasoconstriction, increased plasma renin activity, and decreased aldosterone secretion. The latter results in diuresis and natriuresis and a small increase in serum potassium concentration (mean increases of about 0.25 mEq/L were seen when moexipril was used alone). Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of moexipril remains to be elucidated. Although the principal mechanism of moexipril in blood pressure reduction is believed to be through the renin-angiotensin-aldosterone system, ACE inhibitors have some effect on blood pressure even in apparent low-renin hypertension.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
AAngiotensin-converting enzyme 2
inhibitor
Human
Absorption

Moexipril is incompletely absorbed, with bioavailability as moexiprilat of about 13% compared to intravenous (I.V.) moexipril (both measuring the metabolite moexiprilat), and is markedly affected by food, which reduces Cmax and AUC by about 70% and 40%, respectively, after the ingestion of a low-fat breakfast or by 80% and 50%, respectively, after the ingestion of a high-fat breakfast.

Volume of distribution
  • 183 L
Protein binding

Moexiprilat is approxomately 50% protein bound.

Metabolism

Rapidly converted to moexiprilat, the active metabolite. Conversion to the active metabolite is thought to require carboxyesterases and is likely to occur in organs or tissues, other than the gastrointestinal tract, in which carboxyesterases occur. The liver is thought to be one site of conversion, but not the primary site.

Route of elimination

Moexiprilat undergoes renal elimination.

Half life

Moexipril elimination half-life is approximately 1 hour. Moexiprilat elimination half-life is 2 to 9 hours.

Clearance
  • 441 mL/min
Toxicity

Human overdoses of moexipril have not been reported. In case reports of overdoses with other ACE inhibitors, hypotension has been the principal adverse effect noted. Single oral doses of 2 g/kg moexipril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 3 g/kg. Common adverse effects include cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, and myalgia

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Moexipril Action PathwayDrug action
Moexipril Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Moexipril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Moexipril.Approved, Investigational
AcebutololMoexipril may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Moexipril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Moexipril is combined with Adapalene.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Moexipril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Moexipril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Moexipril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Moexipril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Moexipril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Moexipril.Approved, Illicit, Investigational
AlprenololMoexipril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMoexipril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Moexipril.Experimental, Investigational
AmifostineMoexipril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Moexipril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Moexipril.Illicit, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Moexipril.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Moexipril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Moexipril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Moexipril.Approved, Illicit
AndrographolideThe risk or severity of adverse effects can be increased when Moexipril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Moexipril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Moexipril is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Moexipril.Approved, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Moexipril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Moexipril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Moexipril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.Withdrawn
AzathioprineMoexipril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Moexipril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Moexipril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Moexipril is combined with Balsalazide.Approved, Investigational
BarnidipineMoexipril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Moexipril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Moexipril is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Moexipril.Approved
BenorilateThe risk or severity of adverse effects can be increased when Moexipril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Benzydamine.Approved
BepridilMoexipril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Moexipril.Approved
BethanidineBethanidine may increase the hypotensive activities of Moexipril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Moexipril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Moexipril.Experimental
BimatoprostMoexipril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Moexipril.Approved
BoceprevirThe serum concentration of Moexipril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Moexipril.Approved, Investigational
BQ-123Moexipril may increase the hypotensive activities of BQ-123.Investigational
BretyliumMoexipril may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Moexipril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Moexipril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Moexipril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Bumadizone.Experimental
BumetanideBumetanide may increase the hypotensive activities of Moexipril.Approved
BupranololMoexipril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Moexipril.Approved
CadralazineCadralazine may increase the hypotensive activities of Moexipril.Experimental
CafedrineMoexipril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Moexipril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Moexipril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Moexipril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Moexipril.Experimental
CaptoprilMoexipril may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Moexipril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Moexipril.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Moexipril.Approved
CarvedilolMoexipril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Moexipril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Celecoxib.Approved, Investigational
CeliprololMoexipril may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Moexipril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideMoexipril may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Moexipril.Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Moexipril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Moexipril is combined with Choline magnesium trisalicylate.Approved
CicletanineMoexipril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilMoexipril may increase the hypotensive activities of Cilazapril.Approved
CiprofloxacinMoexipril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Moexipril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Moexipril.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Moexipril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Clonixin.Approved
CloranololMoexipril may increase the hypotensive activities of Cloranolol.Experimental
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Moexipril.Approved
CryptenamineMoexipril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Moexipril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.Approved
CyclopenthiazideMoexipril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Moexipril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Moexipril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Moexipril.Approved, Investigational
DelaprilMoexipril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Moexipril.Approved
DersalazineDersalazine may decrease the antihypertensive activities of Moexipril.Investigational
DeserpidineMoexipril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Moexipril.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Moexipril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Moexipril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Moexipril.Approved, Investigational
DiethylnorspermineMoexipril may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Moexipril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Moexipril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Moexipril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Moexipril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Moexipril.Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Moexipril.Approved
DorzolamideMoexipril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Moexipril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Moexipril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Moexipril.Approved
DrospirenoneMoexipril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Moexipril is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Moexipril is combined with E-6201.Investigational
EfonidipineMoexipril may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Moexipril.Approved, Vet Approved
EnalaprilatMoexipril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Moexipril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Moexipril.Approved, Investigational
EpanololMoexipril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Moexipril.Approved
EpoprostenolMoexipril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Moexipril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Moexipril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Moexipril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Moexipril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Moexipril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Moexipril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Moexipril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Moexipril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Moexipril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Moexipril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Moexipril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Moexipril is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Moexipril is combined with Felbinac.Experimental
FelodipineMoexipril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenbufen.Approved
FenoldopamMoexipril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Moexipril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Feprazone.Experimental
Ferulic acidMoexipril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Moexipril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Moexipril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Moexipril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Moexipril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Moexipril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Moexipril.Approved, Vet Approved
GarlicThe serum concentration of Moexipril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Moexipril.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Moexipril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Moexipril.Approved
GuanazodineMoexipril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMoexipril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Moexipril.Approved, Investigational
GuanoclorMoexipril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMoexipril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMoexipril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Moexipril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Moexipril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Moexipril.Approved, Investigational
HexamethoniumMoexipril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Moexipril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Moexipril is combined with Higenamine.Investigational
HydralazineHydralazine may increase the hypotensive activities of Moexipril.Approved
HydrochlorothiazideMoexipril may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideMoexipril may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Moexipril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Moexipril.Approved
ImidaprilMoexipril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Moexipril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Moexipril.Approved
IndapamideMoexipril may increase the hypotensive activities of Indapamide.Approved
IndenololMoexipril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Moexipril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Moexipril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Moexipril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Moexipril.Experimental
IproniazidIproniazid may increase the hypotensive activities of Moexipril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Moexipril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Moexipril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Moexipril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Moexipril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Moexipril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Moexipril.Approved
LacidipineMoexipril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Moexipril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Moexipril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Moexipril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Moexipril.Approved
LinsidomineMoexipril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilMoexipril may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Moexipril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Moexipril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Moexipril.Experimental
LofexidineMoexipril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Moexipril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Moexipril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Moexipril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Lumiracoxib.Approved, Investigational
MacitentanMoexipril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.Approved
ManidipineMoexipril may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Moexipril is combined with Masoprocol.Approved, Investigational
MecamylamineMecamylamine may increase the hypotensive activities of Moexipril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Moexipril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Moexipril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Moexipril.Experimental
MethoserpidineMoexipril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Moexipril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
MethyldopaMoexipril may increase the hypotensive activities of Methyldopa.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Moexipril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Moexipril.Approved, Investigational
MetipranololMoexipril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Moexipril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Moexipril.Approved, Investigational
MetyrosineMoexipril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMoexipril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Moexipril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Moexipril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Moexipril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Moexipril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Moexipril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Moexipril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Moexipril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Moexipril.Approved, Investigational
MuzolimineMoexipril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabumetone.Approved
NadololMoexipril may increase the hypotensive activities of Nadolol.Approved
NafamostatThe risk or severity of adverse effects can be increased when Moexipril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Moexipril is combined with Naftifine.Approved
NaftopidilMoexipril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Moexipril is combined with Naproxen.Approved, Vet Approved
NebivololMoexipril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Moexipril is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Moexipril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Moexipril.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Moexipril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Niflumic Acid.Approved
NiguldipineMoexipril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMoexipril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Moexipril.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Moexipril.Approved
NitrendipineMoexipril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Moexipril.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Moexipril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Moexipril.Approved
ObinutuzumabMoexipril may increase the hypotensive activities of Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Moexipril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Olsalazine.Approved
OmapatrilatMoexipril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Moexipril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Moexipril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxaprozin.Approved
OxprenololMoexipril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Moexipril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Moexipril is combined with Parthenolide.Investigational
PenbutololMoexipril may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentoliniumMoexipril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Moexipril.Approved, Investigational
PerindoprilMoexipril may increase the hypotensive activities of Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Moexipril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Moexipril.Approved
PhenoxybenzamineMoexipril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhentolamineMoexipril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Moexipril.Withdrawn
PindololMoexipril may increase the hypotensive activities of Pindolol.Approved
PiretanidePiretanide may increase the hypotensive activities of Moexipril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Moexipril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirprofen.Experimental
Platelet Activating FactorMoexipril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideMoexipril may increase the hypotensive activities of Polythiazide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Moexipril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Pregabalin.Approved, Illicit, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Moexipril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Moexipril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Moexipril is combined with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Moexipril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.Approved
PTC299The risk or severity of adverse effects can be increased when Moexipril is combined with PTC299.Investigational
QuinaprilMoexipril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Moexipril.Approved
RamiprilRamipril may increase the hypotensive activities of Moexipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Moexipril.Approved
RemikirenRemikiren may increase the hypotensive activities of Moexipril.Approved
RescinnamineMoexipril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Moexipril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Moexipril is combined with Resveratrol.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Moexipril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Moexipril.Approved
RituximabMoexipril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Rofecoxib.Investigational, Withdrawn
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Moexipril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Moexipril is combined with Sacubitril.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Moexipril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Moexipril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Moexipril.Approved
SelegilineSelegiline may increase the hypotensive activities of Moexipril.Approved, Investigational, Vet Approved
SelexipagMoexipril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Moexipril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Moexipril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Moexipril is combined with Serrapeptase.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Moexipril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Moexipril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Moexipril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Moexipril.Approved, Investigational
SitaxentanMoexipril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Moexipril is combined with Sodium aurothiomalate.Approved
Sodium phosphateMoexipril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilMoexipril may increase the hypotensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Moexipril is combined with SRT501.Investigational
St. John's WortThe metabolism of Moexipril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Moexipril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Moexipril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Moexipril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Moexipril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
TalinololMoexipril may increase the hypotensive activities of Talinolol.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Moexipril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril.Approved, Investigational
TemocaprilMoexipril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Moexipril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Moexipril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Moexipril is combined with Teriflunomide.Approved
TerlipressinMoexipril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineMoexipril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineMoexipril may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Moexipril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tiaprofenic acid.Approved
TiboloneMoexipril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenMoexipril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the hypotensive activities of Moexipril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Moexipril is combined with Tinoridine.Investigational
TipranavirThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Moexipril.Approved
TolazolineMoexipril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Moexipril is combined with Tolmetin.Approved
TolonidineMoexipril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Moexipril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Moexipril.Approved
TorasemideTorasemide may increase the hypotensive activities of Moexipril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Moexipril.Approved
TranilastThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moexipril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Moexipril.Approved
TravoprostTravoprost may increase the hypotensive activities of Moexipril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Moexipril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Moexipril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Moexipril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Moexipril is combined with Tribenoside.Experimental
TrichlormethiazideMoexipril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Moexipril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Moexipril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Moexipril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Moexipril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Moexipril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Moexipril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Moexipril.Approved, Investigational
UnoprostoneMoexipril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Moexipril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Moexipril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Moexipril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Moexipril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Moexipril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Moexipril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Moexipril.Approved, Investigational
VincamineMoexipril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMoexipril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideMoexipril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMoexipril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Moexipril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Moexipril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Moexipril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Moexipril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilMoexipril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Moexipril is combined with Zomepirac.Withdrawn
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of moexipril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of moexipril.
  • Moexipril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take moexipril one hour before or two hours after meals.

References

General References
  1. Asmar R, Sayegh F, Tracz W, Hlawaty M, Olszowska M, Jourde M, Vincent M, Goujoun B, Maldonado J: Reversal of left ventricular hypertrophy with the ACE inhibitor moexipril in patients with essential hypertension. Acta Cardiol. 2002 Feb;57(1):31-2. [PubMed:11918132]
  2. Blacher J, Raison J, Amah G, Schiemann AL, Stimpel M, Safar ME: Increased arterial distensibility in postmenopausal hypertensive women with and without hormone replacement therapy after acute administration of the ACE inhibitor moexipril. Cardiovasc Drugs Ther. 1998 Sep;12(4):409-14. [PubMed:9825188]
  3. Brogden RN, Wiseman LR: Moexipril. A review of its use in the management of essential hypertension. Drugs. 1998 Jun;55(6):845-60. [PubMed:9617599]
  4. Cawello W, Boekens H, Waitzinger J, Miller U: Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. Int J Clin Pharmacol Ther. 2002 Jan;40(1):9-17. [PubMed:11837383]
  5. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  6. Chrysant SG, Chrysant GS: Pharmacological profile and clinical use of moexipril. Expert Rev Cardiovasc Ther. 2003 Sep;1(3):345-52. [PubMed:15030263]
  7. Chrysant GS, Nguyen PK: Moexipril and left ventricular hypertrophy. Vasc Health Risk Manag. 2007;3(1):23-30. [PubMed:17583172]
  8. Grass GM, Morehead WT: Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989 Sep;6(9):759-65. [PubMed:2554270]
  9. Kalasz H, Petroianu G, Tekes K, Klebovich I, Ludanyi K, Gulyas Z: Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS. Med Chem. 2007 Jan;3(1):101-6. [PubMed:17266629]
  10. Persson B, Stimpel M: Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol. 1996;50(4):259-64. [PubMed:8803515]
  11. Spinar J, Vitovec J: MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial. Int J Cardiol. 2005 Apr 20;100(2):199-206. [PubMed:15823625]
  12. Stimpel M, Koch B, Oparil S: Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology. 1998 May;89(4):271-6. [PubMed:9643274]
  13. White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy. 1998 May-Jun;18(3):588-99. [PubMed:9620109]
  14. White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM: Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995 Mar;35(3):233-8. [PubMed:7608310]
External Links
Human Metabolome Database
HMDB0014829
KEGG Compound
C07704
PubChem Compound
91270
PubChem Substance
46508441
ChemSpider
82418
BindingDB
50084673
ChEBI
6960
ChEMBL
CHEMBL1165
Therapeutic Targets Database
DAP000586
PharmGKB
PA164769059
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Moexipril
ATC Codes
C09BA13 — Moexipril and diureticsC09AA13 — Moexipril

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
2CompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Glenmark generics ltd
  • Paddock laboratories inc
  • Teva pharmaceuticals usa inc
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
TabletOral15 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral7.5 mg/1
Tablet, film coatedOral
Tablet, film coatedOral15 mg/1
Prices
Unit descriptionCostUnit
Univasc 15 mg tablet2.44USD tablet
Univasc 7.5 mg tablet2.13USD tablet
Moexipril hcl 15 mg tablet1.48USD tablet
Moexipril hcl 7.5 mg tablet1.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySoluble (about 10% weight-to-volume) in distilled water at room temperature as HCl salt.Not Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00585 mg/mLALOGPS
logP1.52ALOGPS
logP1.5ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.46ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area114.4 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity132.88 m3·mol-1ChemAxon
Polarizability53.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5775
Blood Brain Barrier-0.9022
Caco-2 permeable-0.7313
P-glycoprotein substrateSubstrate0.9085
P-glycoprotein inhibitor IInhibitor0.5919
P-glycoprotein inhibitor IIInhibitor0.8157
Renal organic cation transporterNon-inhibitor0.8146
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.8369
CYP450 3A4 substrateSubstrate0.7014
CYP450 1A2 substrateNon-inhibitor0.8205
CYP450 2C9 inhibitorNon-inhibitor0.5961
CYP450 2D6 inhibitorNon-inhibitor0.8261
CYP450 2C19 inhibitorNon-inhibitor0.6592
CYP450 3A4 inhibitorNon-inhibitor0.5935
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6861
Ames testNon AMES toxic0.8358
CarcinogenicityNon-carcinogens0.9378
BiodegradationNot ready biodegradable0.9762
Rat acute toxicity2.5131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9715
hERG inhibition (predictor II)Inhibitor0.8751
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / N-acyl-L-alpha-amino acids / Alpha amino acid amides / Tetrahydroisoquinolines / Anisoles / Alkyl aryl ethers / Aralkylamines / Fatty acid esters / Benzene and substituted derivatives / Dicarboxylic acids and derivatives
show 10 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid or derivatives / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / Fatty acid ester / Aralkylamine
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
peptide (CHEBI:6960)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin...
Gene Name
ACE2
Uniprot ID
Q9BYF1
Uniprot Name
Angiotensin-converting enzyme 2
Molecular Weight
92462.4 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chrysant SG, Chrysant GS: Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol. 2004 Aug;44(8):827-36. [PubMed:15286086]
  3. Edling O, Bao G, Feelisch M, Unger T, Gohlke P: Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. [PubMed:7473177]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:50